Search results for: 'changes profitability study'

The healthcare landscape is experiencing a profound shift as it shifts away from traditional fee-for-service models toward value-based care. This transition emphasizes collaboration among healthcare stakeholders, fostering a patient-centric approach. The focus is not merely on the quantity of services delivered but also on the quality of care, enco...

Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure ...

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastructure relies on an extensive supply chain involving ...

Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer per...

For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...

Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further ...

This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...

31 Oct 2017  |  Global  |  Market Research

Global Digital Pathology Market, 2017 Companies-To-Action

Collaborative Business Models Embracing Artificial Intelligence Application in Novel Disease Areas to Drive Market Growth

Infographics

×

It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discove...

06 Jun 2018  |  Global  |  Market Research

Cardiometabolic Diseases Market—Trends and Growth Opportunities, Forecast to 2022

Shift Towards a 'Comprehensive Care Continuum' with the Adoption of Integrated Care Pathways that Combine Clinical Therapies with Wellness Programs

Infographics

×

Key Issues Addressed

Globally, cardiometabolic diseases are witnessing a consistent rise in prevalence every year, with hypertension and diabetes among the leading conditions. A rising population of hypertension is, in turn, leading to growing incidence of chronic heart failure with about 26 million cases of CHF globally. Although drug therapies are the first line of t...